| Bioactivity | Inetetamab is a monoclonal antibody binding to domain IV of HER2 receptor. Inetetamab alone or together with tyrosine kinase inhibitors has antitumor activities[1][2]. |
| In Vivo | Inetetamab (20 mg/kg，腹腔注射) 在 JIMT-1 异种移植小鼠模型中显示出抗肿瘤作用[2]。Inetetamab (20 mg/kg, 腹腔注射) 与 Pyrotinib 或 Cyclophosphamide 一起在 JIMT-1 和 NCI-N87 异种移植小鼠模型中也具有明显的抗肿瘤作用[2]。 Animal Model: |
| Name | Inetetamab |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Min Yan, et al. Anti-HER2 antibody inetetamab plus camrelizumab and utidelone for pretreated HER2-positive advanced breast cancer: A single-arm, multicenter, phase 2 study. Journal of Clinical Oncology. 2022. 40 (16), e13030-e13030. [2]. Deng L,et al. Systemic investigation of inetetamab in combination with small molecules to treat HER2-overexpressing breast and gastric cancers. Open Life Sci. 2023 Jan 10;18(1):20220535. |